All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
AML HubGVhD HubLymphoma HubMDS HubMPN HubMultiple Myeloma Hub

Frontline ponatinib with steroids for patients with Ph+ ALL

Apr 29, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in ALL

The ALL Hub is pleased to present a visual abstract representing key data from the phase II INCB84344-201 trial (NCT01641107) evaluating ponatinib plus prednisone as a firstline treatment for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) who are aged ≥60 years or considered ineligible for intensive chemotherapy and stem cell transplantation.


 

Share: